Hypercoagulability Market: By Type, By Drugs, By Route of Administration, By End Users and Region Forecast 2020-2031

download arrow download arrow Download Sample
settings arrow settings arrow email us

Hypercoagulability Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, and Others), By Drugs (Heparin, Warfarin, Vitamin K Antagonist, Direct Thrombin Inhibitors, Others), By Route of Administration (Oral and Injectable), By End Users (Hospitals, Specialty Clinics, Homecare, Others) and Region Forecast 2020-2031

checked icon checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Hypercoagulability Market size was valued at US$ 693.7 million in 2024 and is expected to reach US$ 1,071.0 million by 2031, growing at a significant CAGR of 6.4% from 2025-2031. Hypercoagulability, also known as thrombophilia, is an abnormality of blood coagulation that increases the risk of thrombosis, and the most common conditions associated with thrombophilia are deep vein thrombosis and pulmonary embolism, which are collectively known as venous thromboembolism. According to the Europe PMC, venous thromboembolism has an incidence ranging between 1 and 5 in 1000 per year in the general population. The rising cases of hypercoagulability risk factors such as cancers and heart diseases are driving the market growth. whereas, the cost of treatment might hinder the market growth. The initiatives by governments and non-government organizations will act as an opportunity for the market to expand.

Key Developments

In May 2020, the US FDA approved Deciphera Pharmaceuticals’s Qinlock (Ripretinib) tablets for advanced gastrointestinal stromal tumors.

summary download arrow Download Sample

Hypercoagulability Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

6.4%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Hypercoagulability Market Dynamics

Due to various initiatives from pharmaceutical companies and government organizations, and the increasing risk factors of hypercoagulability, there will be a positive impact on market growth. For instance, in July 2022, the National Blood Clot Alliance established the Council for Emerging Researchers in Thrombosis to serve as a forum for researchers working in thrombosis and thrombophilia to promote and carry out research and scientific activities. However, accessibility to primary care for the patients could pose a hindrance to the market growth.

Hypercoagulability Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 693.7 million

Market Size in 2031

US$ 1,071.0 million

Market CAGR

6.4%

By Type

  • Factor V Leiden
  • Prothrombin 20210
  • Antiphospholipid Syndrome
  • Others

By Drug Class

  • Heparin
  • Warfarin
  • Vitamin K Antagonist
  • Direct Thrombin Inhibitors
  • Others

By Route of Administration

  • Oral
  • Injectable

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The hypercoagulability market report provides granular level information about the market size, regional market share, historic market (2020-2024) and forecast (2025-2031)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Hypercoagulability market size was valued at US$ 693.7 million in 2024 and is expected to reach US$ 1,071.0 million by 2031, growing at a CAGR of 6.4%.

The initiatives by governments and non-government organizations are the key opportunities for the market.

The rising cases of hypercoagulability risk factors such as cancers and heart diseases are the growth drivers in the market.

Yino Pharma Limited, Sanofi, Teva Pharmaceutical Industries Ltd., Shenzhen Hepalink Pharmaceutical, Techdow Pharmaceutical Co., Ltd., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Novartis AG, Nanjing Jianyo, Biochemical Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Fresenius Kabi AG, Eisai Co., Ltd., and Aspen Holdings are a few companies operating in the market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Hypercoagulability Market Introduction 
2.1.Global Hypercoagulability Market  - Taxonomy
2.2.Global Hypercoagulability Market  - Definitions
2.2.1.Type
2.2.2.Drug Class
2.2.3.Route of Administration
2.2.4. End User
2.2.5.Region
3.Global Hypercoagulability Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Hypercoagulability Market Analysis, 2020 - 2024 and Forecast 2025 - 2031
4.1.  Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Hypercoagulability Market  By Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
5.1. Factor V Leiden
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Prothrombin 20210
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Antiphospholipid Syndrome
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Hypercoagulability Market  By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
6.1. Heparin
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Warfarin
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Vitamin K Antagonist
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Direct Thrombin Inhibitors
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Hypercoagulability Market  By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Injectable
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Hypercoagulability Market  By  End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
8.1. Hospitals
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Specialty Clinics
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Homecare
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Others
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
9.Global Hypercoagulability Market  By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Hypercoagulability Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
10.1. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Factor V Leiden
10.1.2.Prothrombin 20210
10.1.3.Antiphospholipid Syndrome
10.1.4.Others
10.2.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Heparin
10.2.2.Warfarin
10.2.3.Vitamin K Antagonist
10.2.4.Direct Thrombin Inhibitors
10.2.5.Others
10.3.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Injectable
10.4.   End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospitals
10.4.2.Specialty Clinics
10.4.3.Homecare
10.4.4.Others
10.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Hypercoagulability Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
11.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Factor V Leiden
11.1.2.Prothrombin 20210
11.1.3.Antiphospholipid Syndrome
11.1.4.Others
11.2.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Heparin
11.2.2.Warfarin
11.2.3.Vitamin K Antagonist
11.2.4.Direct Thrombin Inhibitors
11.2.5.Others
11.3.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Injectable
11.4.   End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospitals
11.4.2.Specialty Clinics
11.4.3.Homecare
11.4.4.Others
11.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Hypercoagulability Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
12.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Factor V Leiden
12.1.2.Prothrombin 20210
12.1.3.Antiphospholipid Syndrome
12.1.4.Others
12.2.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Heparin
12.2.2.Warfarin
12.2.3.Vitamin K Antagonist
12.2.4.Direct Thrombin Inhibitors
12.2.5.Others
12.3.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Injectable
12.4.   End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospitals
12.4.2.Specialty Clinics
12.4.3.Homecare
12.4.4.Others
12.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Hypercoagulability Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
13.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Factor V Leiden
13.1.2.Prothrombin 20210
13.1.3.Antiphospholipid Syndrome
13.1.4.Others
13.2.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Heparin
13.2.2.Warfarin
13.2.3.Vitamin K Antagonist
13.2.4.Direct Thrombin Inhibitors
13.2.5.Others
13.3.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Injectable
13.4.   End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospitals
13.4.2.Specialty Clinics
13.4.3.Homecare
13.4.4.Others
13.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Hypercoagulability Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
14.1. Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Factor V Leiden
14.1.2.Prothrombin 20210
14.1.3.Antiphospholipid Syndrome
14.1.4.Others
14.2.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Heparin
14.2.2.Warfarin
14.2.3.Vitamin K Antagonist
14.2.4.Direct Thrombin Inhibitors
14.2.5.Others
14.3.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Injectable
14.4.   End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospitals
14.4.2.Specialty Clinics
14.4.3.Homecare
14.4.4.Others
14.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Yino Pharma Limited
15.2.2.Sanofi
15.2.3.Teva Pharmaceutical Industries Ltd.
15.2.4.Shenzhen Techdow Pharmaceutical Co., Ltd.
15.2.5.Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
15.2.6.Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
15.2.7.Novartis AG
15.2.8.Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
15.2.9.Hikma Pharmaceuticals PLC
15.2.10.Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
15.2.11.Fresenius Kabi AG
15.2.12.Eisai Co., Ltd.
15.2.13.Aspen Holdings
15.2.14.Mylan N.V.
15.2.15.Hoffmann-La Roche Ltd.
15.2.16.Pfizer Inc.
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Yino Pharma Limited
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Shenzhen Techdow Pharmaceutical Co., Ltd.
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Novartis AG
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Fresenius Kabi AG
  • Eisai Co., Ltd.
  • Aspen Holdings
  • Mylan N.V.
  • Hoffmann-La Roche Ltd.
  • Pfizer Inc.

Related Industry Reports

Antiphospholipid Syndrome Market

Generic Injectables Market